Skip to main content
Erschienen in:

17.06.2022 | Original Article

SARS CoV-2 reinfection rate is higher in the Omicron variant than in the Alpha and Delta variants

verfasst von: Osman Özüdoğru, Yasemin Genç Bahçe, Ömer Acer

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Background and objectives

Many mutations in variants for instance Delta and Alpha are associated with immune evasion and higher infectious potential. There are uncertainties regarding Omicron. In this regard, we aimed to compare the frequency of reinfection of SARS CoV-2 variants in our hospital between April 22, 2021 and January 26, 2022.

Method

The reinfection rates and demographic characteristics of a total of 27,487 COVID-19 patients infected with different SARS CoV-2 variants were examined.

Results

Reinfection was found in 26 (0.46%) of 5554 Alpha, 209 (1.16%) of 17,941 Delta, and 520 (13.0%) of 3992 Omicron variants. A statistically significant difference was observed between the reinfection rates of the variants (p = 0.000). The mean reinfection days were calculated as 204.4 ± 51.1 in the Alpha variant, 291.2 ± 58.2 in the Delta variant, and 361.2 ± 131.6 in the Omicron variant (p = 0.000). It was observed that 16.5% of reinfection cases caught COVID-19 for the second time 3–6 months after the first COVID-19 infection, 36.7% after 6–12 months, and 46.8% after more than 12 months. There was a significant difference between the times in reinfection cases. Most reinfections occurred more than 12 months apart. Among those with a reinfection time > 12 months, 0% had Alpha, 3.4% had Delta, and 96.6% had Omicron variants.

Conclusion

The highest reinfection rate was observed in the Omicron variant. Reinfection was approximately 30 times more frequent in the Omicron variant than in the Alpha variant and 10 times more frequent in the Delta variant.
Literatur
3.
Zurück zum Zitat Twohig KA, Nyberg T, Zaidi A et al (2022) Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B 1 617 2) compared with alpha (B. 1. 1. 7) variants of concern a cohort study. Lancet Inf Dis 22(1):35–42CrossRef Twohig KA, Nyberg T, Zaidi A et al (2022) Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B 1 617 2) compared with alpha (B. 1. 1. 7) variants of concern a cohort study. Lancet Inf Dis 22(1):35–42CrossRef
4.
Zurück zum Zitat Karim SSA, Karim QA (2021) Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. The Lancet 398(10317):2126–2128CrossRef Karim SSA, Karim QA (2021) Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. The Lancet 398(10317):2126–2128CrossRef
5.
Zurück zum Zitat Ren S-Y, Wang W-B, Gao R-D et al (2022) Omicron variant (B. 1. 1. 529) of SARS-CoV-2 mutation infectivity transmission and vaccine resistance. World J Clin Cases 10:1–5CrossRefPubMedPubMedCentral Ren S-Y, Wang W-B, Gao R-D et al (2022) Omicron variant (B. 1. 1. 529) of SARS-CoV-2 mutation infectivity transmission and vaccine resistance. World J Clin Cases 10:1–5CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat El-Shabasy RM, Nayel MA, Taher MM et al (2022) Three wave changes, new variant strains, and vaccination effect against COVID-19 pandemic. Int J Biol Macromol 204:161–168CrossRefPubMedPubMedCentral El-Shabasy RM, Nayel MA, Taher MM et al (2022) Three wave changes, new variant strains, and vaccination effect against COVID-19 pandemic. Int J Biol Macromol 204:161–168CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Chen J, Wang R, Gilby NB et al (2022) Omicron variant (B. 1.1. 529): infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model 62:412–422CrossRefPubMed Chen J, Wang R, Gilby NB et al (2022) Omicron variant (B. 1.1. 529): infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model 62:412–422CrossRefPubMed
9.
Zurück zum Zitat Papanikolaou V, Chrysovergis A, Ragos V et al (2022) From Delta to Omicron: S1-RBD/S2 mutation/deletion equilibrium in SARS-CoV-2 defined variants. Gene 146134 Papanikolaou V, Chrysovergis A, Ragos V et al (2022) From Delta to Omicron: S1-RBD/S2 mutation/deletion equilibrium in SARS-CoV-2 defined variants. Gene 146134
10.
Zurück zum Zitat Siddiqui SM, Bowman KA, Zhu AL et al (2022) Serological markers of SARS-CoV-2 reinfection. mBio 13(1):e02141–02121 Siddiqui SM, Bowman KA, Zhu AL et al (2022) Serological markers of SARS-CoV-2 reinfection. mBio 13(1):e02141–02121
12.
Zurück zum Zitat Kojima N, Roshani A, Brobeck M, Baca A, Klausner JD (2021) Incidence of severe acute respiratory syndrome coronavirus-2 infection among previously infected or vaccinated employees. medRxiv Kojima N, Roshani A, Brobeck M, Baca A, Klausner JD (2021) Incidence of severe acute respiratory syndrome coronavirus-2 infection among previously infected or vaccinated employees. medRxiv
13.
Zurück zum Zitat Thompson MG, Burgess JL, Naleway AL et al (2021) Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight US locations, December 2020–March 2021. Morb Mortal Wkly Rep 70(13):495CrossRef Thompson MG, Burgess JL, Naleway AL et al (2021) Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight US locations, December 2020–March 2021. Morb Mortal Wkly Rep 70(13):495CrossRef
14.
Zurück zum Zitat Poland GA, Ovsyannikova IG, Kennedy RB (2020) SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. The Lancet 396(10262):1595–1606CrossRef Poland GA, Ovsyannikova IG, Kennedy RB (2020) SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. The Lancet 396(10262):1595–1606CrossRef
15.
Zurück zum Zitat Hall VJ, Foulkes S, Charlett A et al (2021) SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). The Lancet 397(10283):1459–1469CrossRef Hall VJ, Foulkes S, Charlett A et al (2021) SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). The Lancet 397(10283):1459–1469CrossRef
16.
Zurück zum Zitat Kojima N, Shrestha N, Klausner JD (2021) A systematic review of the protective effect of prior SARS-CoV-2 infection on repeat infection. Eval Health Prof 44(4):327–332CrossRefPubMedPubMedCentral Kojima N, Shrestha N, Klausner JD (2021) A systematic review of the protective effect of prior SARS-CoV-2 infection on repeat infection. Eval Health Prof 44(4):327–332CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Lumley SF, O’Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, Marsden BD, Cox S, James T, Warren F (2021) Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med 384(6):533–540CrossRefPubMed Lumley SF, O’Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, Marsden BD, Cox S, James T, Warren F (2021) Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med 384(6):533–540CrossRefPubMed
18.
Zurück zum Zitat Vitale J, Mumoli N, Clerici P et al (2021) Assessment of SARS-CoV-2 reinfection 1 year after primary infection in a population in Lombardy. Italy JAMA Intern Med 181(10):1407–1408CrossRefPubMed Vitale J, Mumoli N, Clerici P et al (2021) Assessment of SARS-CoV-2 reinfection 1 year after primary infection in a population in Lombardy. Italy JAMA Intern Med 181(10):1407–1408CrossRefPubMed
19.
Zurück zum Zitat Perez G, Banon T, Gazit S et al (2021) A 1 to 1000 SARS-CoV-2 reinfection proportion in members of a large healthcare provider in Israel: a preliminary report. MedRxiv Perez G, Banon T, Gazit S et al (2021) A 1 to 1000 SARS-CoV-2 reinfection proportion in members of a large healthcare provider in Israel: a preliminary report. MedRxiv
20.
Zurück zum Zitat Graham MS, Sudre CH, May A et al (2021) Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B 1 1 7 an ecological study. The Lancet Public Health 6(5):e335–e345CrossRefPubMedPubMedCentral Graham MS, Sudre CH, May A et al (2021) Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B 1 1 7 an ecological study. The Lancet Public Health 6(5):e335–e345CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Turabelidze G, Womack A, Mobley E et al (2021) Garikapaty V, Finley S: SARS-CoV-2 reinfections during the Delta variant surge-Missouri, June–October, 2021. Mo Med 118(6):539PubMedPubMedCentral Turabelidze G, Womack A, Mobley E et al (2021) Garikapaty V, Finley S: SARS-CoV-2 reinfections during the Delta variant surge-Missouri, June–October, 2021. Mo Med 118(6):539PubMedPubMedCentral
22.
Zurück zum Zitat Corrao G, Franchi M, Rea F et al (2022) Protective action of natural and induced immunization against the occurrence of delta or alpha variants of SARS-CoV-2 infection: a test-negative case-control study. BMC Med 20(1):1–10CrossRef Corrao G, Franchi M, Rea F et al (2022) Protective action of natural and induced immunization against the occurrence of delta or alpha variants of SARS-CoV-2 infection: a test-negative case-control study. BMC Med 20(1):1–10CrossRef
23.
Zurück zum Zitat Altarawneh HN, Chemaitelly H, Hasan MR et al (2022) Protection against the Omicron variant from previous SARS-CoV-2 infection. N Eng J Med Altarawneh HN, Chemaitelly H, Hasan MR et al (2022) Protection against the Omicron variant from previous SARS-CoV-2 infection. N Eng J Med
24.
Zurück zum Zitat Callaway E (2021) Omicron likely to weaken COVID vaccine protection. Nature 600(7889):367–368CrossRefPubMed Callaway E (2021) Omicron likely to weaken COVID vaccine protection. Nature 600(7889):367–368CrossRefPubMed
25.
Zurück zum Zitat Abu-Raddad LJ, Chemaitelly H, Ayoub HH et al (2021) Introduction and expansion of the SARS-CoV-2 B. 1.1. 7 variant and reinfections in Qatar: A nationally representative cohort study. PLoS Med 18(12) Abu-Raddad LJ, Chemaitelly H, Ayoub HH et al (2021) Introduction and expansion of the SARS-CoV-2 B. 1.1. 7 variant and reinfections in Qatar: A nationally representative cohort study. PLoS Med 18(12)
26.
Zurück zum Zitat Chemaitelly H, Bertollini R, Abu-Raddad LJ et al (2021) Efficacy of natural immunity against SARS-CoV-2 reinfection with the beta variant. N Eng J Med 385(27):2585–2586CrossRef Chemaitelly H, Bertollini R, Abu-Raddad LJ et al (2021) Efficacy of natural immunity against SARS-CoV-2 reinfection with the beta variant. N Eng J Med 385(27):2585–2586CrossRef
27.
Zurück zum Zitat Kim P, Gordon SM, Sheehan MM et al (2021) Duration of SARS-CoV-2 natural immunity and protection against the Delta variant: a retrospective cohort study. Clin Infect Dis XX(XX):1–6 Kim P, Gordon SM, Sheehan MM et al (2021) Duration of SARS-CoV-2 natural immunity and protection against the Delta variant: a retrospective cohort study. Clin Infect Dis XX(XX):1–6
28.
Zurück zum Zitat Brits E, Adepoju P (2021) Omicron potential under close scrutiny. Nature 10:197–199 Brits E, Adepoju P (2021) Omicron potential under close scrutiny. Nature 10:197–199
Metadaten
Titel
SARS CoV-2 reinfection rate is higher in the Omicron variant than in the Alpha and Delta variants
verfasst von
Osman Özüdoğru
Yasemin Genç Bahçe
Ömer Acer
Publikationsdatum
17.06.2022
Verlag
Springer International Publishing
Erschienen in
Irish Journal of Medical Science (1971 -) / Ausgabe 2/2023
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-022-03060-4

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Verbände und Cremes gegen Dekubitus: „Wir wissen nicht, was sie bringen!“

Die Datenlage zur Wirksamkeit von Verbänden oder topischen Mitteln zur Prävention von Druckgeschwüren sei schlecht, so die Verfasser einer aktuellen Cochrane-Studie. Letztlich bleibe es unsicher, ob solche Maßnahmen den Betroffenen nutzen oder schaden.

Schützt das tägliche Glas Milch vor Darmkrebs?

Die Milch machts – sie bietet Frauen nach Daten einer großen Ernährungsanalyse den besten Darmkrebsschutz aller Lebensmittel, was am hohen Kalziumgehalt liegen dürfte. Am anderen Ende des Spektrums steht der Alkoholkonsum: Das Glas Wein am Abend ist eher ungünstig.

Vorsicht mit Glukokortikoiden bei Glomerulopathie

Auch niedrig dosierte Glukokortikoide zur Behandlung einer primären Glomerulopathie lassen offenbar die Infektionsgefahr steigen. In einer US-Studie hing das Risiko vor allem mit der kombinierten Anwendung von Immunsuppressiva zusammen.

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.